skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Estradiol valerate and dienogest: a new approach to oral contraception

Review

(1602) Views  (405) Full article downloads

Authors: Kiley JW, Shulman LP

Published Date August 2011 Volume 2011:3 Pages 281 - 286
DOI: http://dx.doi.org/10.2147/IJWH.S22645

Jessica W Kiley, Lee P Shulman
Section of Family Planning and Contraception, Department of Obstetrics and Gynecology, Feinberg School of Medicine of Northwestern University, Chicago, IL, USA

Abstract: Most combination oral contraceptives contain ethinyl estradiol and a progestin. A new and novel oral contraceptive formulation combines estradiol valerate (E2V) with dienogest (DNG) in a four-phase dosing regimen. 17β-estradiol is a naturally-occurring estrogen, and a contraceptive pill containing such an estrogen offers potential benefits with regard to metabolic side effects and adverse events. Dienogest is derived from 19-nortestosterone and exerts profound progestational effects on the endometrium, but it differs from other progestins in its class by its antiandrogenic activity. Estradiol valerate plus dienogest (E2V/DNG) is now available in a four-phasic regimen that integrates an estrogen stepdown and progestin stepup dosing approach along with a short two-day hormone-free interval. This regimen offers safe, reliable contraception and has been shown to be an effective treatment for heavy menstrual bleeding. Metabolic effects and adverse events appear similar to those reported with oral contraceptives containing ethinyl estradiol.

Keywords: estradiol valerate, dienogest, oral contraception, combination






 

Other articles by Dr Jessica Kiley



Readers of this article also read:

Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
Estrogens of multiple classes and their role in mental health disease mechanisms
Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill
Current and emerging treatments for uterine myoma – an update
Randomized clinical trial evaluating the frequency of membrane sweeping with an unfavorable cervix at 39 weeks
Medical management of recurrent endometrioma with long-term norethindrone acetate